Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI’s) prolonged survival in molecularly unselected advanced non-small cell lung cancer (NSCLC) patients receiving second or third line therapy and in the maintenance setting [1–3]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.